News & Perspective

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Oct 26, 2007

Oct 26, 2007

THE PANDEMIC VACCINE PUZZLE Part 2: Vaccine production capacity falls far short

Editor's note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Dec 29, 2006

Dec 29, 2006

Feds detail progress on pandemic preparedness

(CIDRAP News) – In a recent update on pandemic influenza preparedness planning, the US government reported meeting more than 90% of a long list of objectives it set for itself about 6 months ago.

The report charts progress on a wide range of preparedness measures, from shoring up laboratory capabilities to planning for distribution of critical medical supplies and preparing checklists for various sectors of the economy.

Oct 04, 2006

Oct 04, 2006

Groups call for pandemic flu vaccine 'master plan'

(CIDRAP News) – Public health and infectious disease experts today called on the United States to develop a "master plan" for development of pandemic influenza vaccines in order to translate scientific advances more rapidly into improved pandemic preparedness.

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»